• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

inflammatory Bowel Disease

Pharma & Human Health

BiomX Licenses Novel Bacterial Targets for the Treatment of Inflammatory Bowel Disease

January 30, 2018 Microbiome Times

NESS ZIONA, Israel, Jan. 30, 2018 /PRNewswire/ — BiomX Ltd., a microbiome company developing customized phage therapies, today announced that it has exclusively sub-licensed from JSR Corporation a set of bacterial targets for the development and […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
  • DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
    May 10, 2023
  • Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
    April 27, 2023
  • Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
    April 25, 2023
  • Researchers create virus-resistant, safely restrained E. coli
    April 10, 2023
sign up

Sign up to the Microbiome Times newsletter